Amgen is a biotechnology company focused on developing and manufacturing innovative therapies for serious illnesses. Its core products include biologic medicines for cancer, kidney disease, and inflammatory disorders. Major business segments encompass oncology, nephrology, and inflammation, with primary revenue sources derived from sales of its flagship drugs, including Enbrel and Neulasta. The company also invests in research and development to expand its product pipeline.
The investment profile of Amgen is more aligned with dividends and value investors, given its consistent dividend yield and established market presence. The stock exhibits moderate volatility and has shown resilience in its earnings, making it suitable for those seeking stable returns. Investors may consider a medium to long-term horizon for potential growth, while the liquidity is moderate, reflecting a balanced approach to investment.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-23 | Sell | Buy | Mixed performance; cautious outlook on revenue decline. |
| 2026-06-19 | Buy | Sell | Weak momentum and fundamentals raise uncertainty. |
| 2026-06-15 | Hold | Buy | Solid fundamentals but mixed momentum signals. |
| 2026-06-05 | Sell | Hold | Mixed performance; monitor for recovery signals. |
| 2026-06-03 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-26 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-18 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-08 | — | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-02 | Buy | Hold | Компания Amgen демонстрирует стабильный рост выручки и дивидендную доходность, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе. |
| 2026-01-21 | Hold | Buy | Компания Amgen демонстрирует положительную динамику цен на акции за последние 60 и 120 дней, что указывает на устойчивый рост. Несмотря на отсутствие данных по EPS и доходам, текущие тренды и momentum предполагают хороши |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-13 | UBS | Target Raised | 400 → 420 | 358.68 |
| 2026-07-13 | Guggenheim | Target Raised | — → 343 | 363.39 |
| 2026-07-08 | Morgan Stanley | Target Lowered | 340 → 333 | 368.1 |
| 2026-07-01 | BMO Capital | Update | — → 400 | 362.4476 |
| 2026-06-16 | Mizuho Securities | Target Raised | — → 303 | 350.53 |
| 2026-06-09 | Morgan Stanley | Target Raised | — → 340 | 344.565 |
| 2026-06-05 | Goldman Sachs | Target Lowered | 425 → 389 | 352.62 |
| 2026-05-14 | Piper Sandler | Target Lowered | 432 → 427 | 336.45 |
| 2026-05-04 | Guggenheim | Target Lowered | 351 → 340 | 329.82 |
| 2026-05-01 | Morgan Stanley | Target Raised | 326 → 332 | 329.305 |
| 2026-04-20 | Canaccord Genuity | Update | — → 366 | 350.16 |
| 2026-04-10 | Morgan Stanley | Target Raised | 309 → 326 | 352.59 |
| 2026-04-09 | Guggenheim | Target Raised | 347 → 351 | 355.6 |
| 2026-04-08 | Truist Financial | Target Raised | 319 → 325 | 349.81 |
| 2026-03-10 | Jefferies | Update | — → 350 | 373.07501 |
| 2026-03-05 | Leerink Partners | Update | — → 355 | 367.6 |
| 2026-02-19 | Barclays | Update | — → 185 | 375.5 |
| 2026-02-19 | Wells Fargo | Target Raised | 325 → 375 | 379.73 |
| 2026-02-18 | Piper Sandler | Target Raised | 381 → 432 | 373.36 |
| 2026-02-11 | Mizuho Securities | Target Raised | 280 → 295 | 364.65 |
